Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of fostamatinib in rheumatoid arthritis after biologic failure
2008-000743-34Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Fostamatinib disodium with Placebo (2 arms). Primary endpoint: ACR20 response rate at Month 3. Started Apr 2008; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000743-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000743-34.